Temasek cuts stake in Celltrion and affiliate for $1b

Singapore’s sovereign wealth fund continues to fine-tune portfolio as it sells a small chunk of its shareholding in South Korea’s Celltrion and Celltrion Healthcare in overnight block deal.

Temasek cashed out part of its investment in South Korean biopharmaceutical firm Celltrion and its affiliate Celltrion Healthcare for a combined W1.07 trillion $994 million on Tuesday, as the Singaporean sovereign wealth fund continues to reshape its portfolio to address long-term opportunities.

In a rare deal that involved two listed companies, Temasek reaped $701 million from the sale of a 1.8% interest in Celltrion and $293 million from another 2.1% stake in Celltrion Healthcare. The latter is the biosimilar unit of Celltrion that listed on the Kosdaq market in July last year.

The divestment, made through Temasek's subsidiary Ion Investments, was conducted at a time...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222